Roivant Sciences has had a bumpy couple of years, but that isn’t stopping investors from pouring more money into the four-year-old company, which aims to one day be a giant holding company for dozens of independent biopharmaceutical spinoffs — and is fulfilling that vision by creating one independent company at a time. Roivant’s newest financing […]